Teduglutide Disease Interactions
There are 5 disease interactions with teduglutide:
teduglutide (Includes teduglutide) ↔ intestinal obstruction
Moderate Potential Hazard, Moderate plausibility. Applies to: Intestinal Obstruction
Intestinal obstruction has been reported in clinical trials with teduglutide. In patients who develop intestinal or stomal obstruction, treatment with teduglutide should be temporarily discontinued while the patient is clinically managed. Treatment may be restarted when the obstructive episode resolves, if clinically indicated. Caution is advised in patients with risk factors for intestinal obstruction.
Teduglutide (Includes teduglutide) ↔ biliary and pancreatic disease
Moderate Potential Hazard, Moderate plausibility. Applies to: Cholelithiasis, Pancreatitis
Cholecystitis, cholangitis, cholelithiasis, and pancreatitis have been reported in clinical studies with teduglutide. For identification of the onset or worsening of gallbladder/biliary/pancreatic disease, patients should undergo laboratory assessment of bilirubin, alkaline phosphatase, lipase and amylase within 6 months prior to starting teduglutide, and at least every 6 months while on treatment; or more frequently if needed. If clinically meaningful changes are seen, further evaluation including imaging of the gallbladder, biliary tract and/or pancreas is recommended; and the need for continued teduglutide treatment should be reassessed.
Teduglutide (Includes teduglutide) ↔ congestive heart failure
Moderate Potential Hazard, Moderate plausibility. Applies to: Cardiovascular Disease, Fluid Retention
Fluid overload and congestive heart failure have been observed in clinical trials with teduglutide. This was probably related to enhanced fluid absorption associated with the medication. If fluid overload occurs, parenteral support should be adjusted and treatment should be reassessed, especially in patients with underlying cardiovascular disease. If significant cardiac deterioration develops while on teduglutide, the need to continue treatment should be reassessed.
Teduglutide (Includes teduglutide) ↔ liver impairment
Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease
Teduglutide pharmacokinetics has not been assessed in patients with severe hepatic impairment. Caution and monitoring is advised. Patients with moderate hepatic impairment showed lower Cmax and AUC when compared to healthy matched control subjects after a single subcutaneous dose of teduglutide. However, no dose adjustment is necessary for patients with mild and moderate liver impairment.
Teduglutide (Includes teduglutide) ↔ renal impairment
Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction
Teduglutide is primarily cleared by the kidney and caution is advised when using in patients with moderate to severe renal impairment. The manufacturers recommend to reduced the dose by 50% in patients with moderate and severe renal impairment (creatinine clearance less than 50 mL/min), and end-stage renal disease.
Teduglutide drug interactions
There is 1 drug interaction with teduglutide
Teduglutide alcohol/food interactions
There is 1 alcohol/food interaction with teduglutide
More about teduglutide
- Teduglutide Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- Drug class: miscellaneous GI agents
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.